Wells Fargo’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-782
| Closed | -$258 | – | 7763 |
|
|
2023
Q1 | $258 | Buy |
782
+1
| +0.1% | +$1 | ﹤0.01% | 6706 |
|
|
2022
Q4 | $562 | Buy |
781
+2
| +0.3% | +$2 | ﹤0.01% | 6354 |
|
|
2022
Q3 | $1K | Sell |
779
-1
| -0.1% | -$1 | ﹤0.01% | 6547 |
|
|
2022
Q2 | $0 | Buy |
780
+6
| +0.8% | +$9 | ﹤0.01% | 7849 |
|
|
2022
Q1 | $2K | Hold |
774
| – | – | ﹤0.01% | 6726 |
|
|
2021
Q4 | $1K | Sell |
774
-2,899
| -79% | -$5.84K | ﹤0.01% | 7123 |
|
|
2021
Q3 | $10K | Sell |
3,673
-253
| -6% | -$772 | ﹤0.01% | 6218 |
|
|
2021
Q2 | $12K | Sell |
3,926
-186
| -5% | -$597 | ﹤0.01% | 6096 |
|
|
2021
Q1 | $16K | Sell |
4,112
-8,675
| -68% | -$37.7K | ﹤0.01% | 6219 |
|
|
2020
Q4 | $45K | Sell |
12,787
-12,770
| -50% | -$53.9K | ﹤0.01% | 5619 |
|
|
2020
Q3 | $167K | Buy |
25,557
+10,925
| +75% | +$74.1K | ﹤0.01% | 5041 |
|
|
2020
Q2 | $108K | Sell |
14,632
-9,943
| -40% | -$67.7K | ﹤0.01% | 5195 |
|
|
2020
Q1 | $116K | Sell |
24,575
-3,722
| -13% | -$40K | ﹤0.01% | 4989 |
|
|
2019
Q4 | $365K | Buy |
28,297
+4,961
| +21% | +$45.8K | ﹤0.01% | 4596 |
|
|
2019
Q3 | $245K | Buy |
23,336
+3,823
| +20% | +$50K | ﹤0.01% | 4842 |
|
|
2019
Q2 | $332K | Sell |
19,513
-7,475
| -28% | -$202K | ﹤0.01% | 4659 |
|
|
2019
Q1 | $910K | Buy |
26,988
+9,542
| +55% | +$319K | ﹤0.01% | 3944 |
|
|
2018
Q4 | $509K | Sell |
17,446
-2,023
| -10% | -$89.7K | ﹤0.01% | 4329 |
|
|
2018
Q3 | $1.2M | Buy |
19,469
+3,451
| +22% | +$234K | ﹤0.01% | 3827 |
|
|
2018
Q2 | $1.18M | Buy |
16,018
+11,933
| +292% | +$930K | ﹤0.01% | 3880 |
|
|
2018
Q1 | $268K | Sell |
4,085
-2,338
| -36% | -$177K | ﹤0.01% | 4814 |
|
|
2017
Q4 | $541K | Sell |
6,423
-1,077
| -14% | -$106K | ﹤0.01% | 4334 |
|
|
2017
Q3 | $866K | Sell |
7,500
-607
| -7% | -$63.9K | ﹤0.01% | 3949 |
|
|
2017
Q2 | $947K | Buy |
8,107
+499
| +7% | +$61.9K | ﹤0.01% | 3775 |
|
|
2017
Q1 | $939K | Buy |
7,608
+3,624
| +91% | +$475K | ﹤0.01% | 3800 |
|
|
2016
Q4 | $543K | Buy |
3,984
+2,831
| +246% | +$503K | ﹤0.01% | 4148 |
|
|
2016
Q3 | $229K | Buy |
1,153
+713
| +162% | +$123K | ﹤0.01% | 4401 |
|
|
2016
Q2 | $57K | Sell |
440
-55
| -11% | -$6.12K | ﹤0.01% | 5145 |
|
|
2016
Q1 | $46K | Buy |
495
+52
| +12% | +$5.66K | ﹤0.01% | 5250 |
|
|
2015
Q4 | $90K | Hold |
443
| – | – | ﹤0.01% | 4988 |
|
|
2015
Q3 | $64K | Sell |
443
-196
| -31% | -$36K | ﹤0.01% | 5170 |
|
|
2015
Q2 | $136K | Buy |
639
+599
| +1,498% | +$147K | ﹤0.01% | 4837 |
|
|
2015
Q1 | $9K | Buy |
+40
| New | +$9.68K | ﹤0.01% | 5669 |
|
Other funds holding BLCM
BC
BRWA
TCM
PGAM
Wells Fargo's BLCM Position: Q2 2023 in Review
Wells Fargo sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q2 2023, closing a stake of 782 shares — an estimated $258 sold.
Wells Fargo first reported a position in BLCM in Q1 2015 and held it in 33 quarters. The position peaked at $1.2M in Q3 2018. 4 funds tracked by Wall St. Rank hold BLCM as of Q2 2023.
- Wells Fargo reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q2 2023 after selling out during the quarter.
- Wells Fargo sold 782 Bellicum Pharmaceuticals, Inc. shares in Q2 2023, an estimated $258.
- Wells Fargo first reported a position in Bellicum Pharmaceuticals, Inc. in Q1 2015 and held it in 33 quarters.
- Wells Fargo's Bellicum Pharmaceuticals, Inc. position peaked at $1.2M in Q3 2018.
- 4 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q2 2023.
Based on Wells Fargo's 13F filing for Q2 2023, filed 15 Aug 2023.